Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear

Executive Summary

Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.

You may also be interested in...



COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick

The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.

Earnings Roundup: Specialty/Smaller Biopharmas See Modest Hit From Pandemic

First quarter financials and COVID-19 impacts from Bausch, Neurocrine, Theravance, Ironwood, Rigel.

Keeping Track Of US FDA Decisions: Approvals For Ongentys And New Keytruda, Darzalex Dosing, But Not For Trevyent

The latest US FDA approval decision news and highlights from the Pink Sheet’s FDA Performance Tracker

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel